59146-67-7

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Cyano-2,3-dimethylpyridine serves as a crucial building block in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of new drug molecules with potential therapeutic applications, making it a valuable component in medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical industry, 6-Cyano-2,3-dimethylpyridine is utilized as a key intermediate in the development of pesticides and other crop protection agents. Its incorporation into these products can enhance their effectiveness in protecting crops from pests and diseases.
Used as a Reagent in Organic Chemistry:
6-Cyano-2,3-dimethylpyridine also functions as a reagent in organic chemical reactions, facilitating the synthesis of complex organic molecules. Its presence can influence reaction pathways and outcomes, making it an important tool in organic synthesis.
Used in the Production of New Materials:
6-Cyano-2,3-dimethylpyridine has potential applications in the development of innovative materials, such as polymers and other advanced materials with unique properties. Its versatility in chemical reactions makes it a promising candidate for material science research and development.
Used as an Intermediate in the Chemical Industry:
6-Cyano-2,3-dimethylpyridine is recognized as an important intermediate in the broader chemical industry. Its role in the synthesis of a wide range of products underscores its significance in various chemical processes and manufacturing pathways.
Safety Considerations:
Given the potential hazards associated with 6-Cyano-2,3-dimethylpyridine, it is imperative to handle 6-Cyano-2,3-dimethylpyridine with care. Adherence to safety protocols and proper protective measures are essential when working with this chemical to minimize risks and ensure the safety of personnel and the environment.

Upstream product

• 22710-07-2 2,3-dimethylpyridine 1-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 60-29-7 diethyl ether 
• 88-10-8 N,N-diethylcarbamyl chloride 
• 583-61-9 2,3-Lutidine 

Downstream Products

• 543713-56-0 (5,6-dimethylpyridin-2-yl)methanamine 
• 83282-49-9 5,6-dimethyl-pyridine-2-carboxylic acid 
• 153646-65-2 2-hydroxymethyl-5,6-dimethylpyridine 

Relevant academic research and scientific papers

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

5-lipoxygenase-activating protein (FLAP) inhibitors. Part 4: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin- 2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor

The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem.2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett.2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacokinetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair

The structure-activity relationship of a series of styrylpyridine analogs of MK-0476 (montelukast, Singular) is described. This work has led to the identification of a number of potent and orally active cysLT1 receptor (LTD4 receptor) antagonists including 2ab (L-733,321) as an optimized candidate.

PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS

Compounds having the formula I: STR1 are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.